Stories of Hope, Progress, and Inspiration
Hear from the teams, partners, and families that make up the Beat Childhood Cancer allegiance.
Cancer Therapies are Not Like Shoes
iwilfin™ - Beat Childhood Cancer
DFMO 50% Statistics
DFMO is a drug pending approval with the FDA for kids with neuroblastoma - an extraordinarily deadly cancer. DFMO is a very well-tolerated drug, a testament to its safety. But here's the game-changer: it slashes the risk of relapse by 50%.
IWILFIN™ Approval
Beat Childhood Cancer helped to fund a small group of doctors and researchers who discovered that an existing drug called DFMO could be used to save the lives of children who have had a rare and deadly cancer called Neuroblastoma. DFMO is now known as IWILFIN following approval by the FDA to use the drug as ‘maintenance therapy’ following standard of care treatments.
Patient & Family Stories
Caroline
The Lantz family lives in Nashville, Tennessee, where Caroline is beating neuroblastoma at Monroe Carell Jr. Children’s Hospital at Vanderbilt, on one of the Beat Childhood Cancer clinical trials.
Ezra
Ezra loved trains, Elmo, and dancing. He laughed and smiled often through his cancer treatment, diagnosed on the 400th day of his life with stage 4 neuroblastoma. Because of Ezra, we are better.
Jack
Jack was 4 years old when he was diagnosed with stage 4 neuroblastoma in 2005, and battled cancer nearly 7 years, before finding his ultimate cure in Heaven in 2012.
Parker
Parker is from San Diego, CA and was diagnosed with neuroblastoma in 2013. His family started a nonprofit called Team Parker for Life and has helped to fund the Beat Childhood Cancer clinical trial Parker completed. Today, Parker is cancer-free.
Blogs from our team
Support the Beat Childhood Cancer Foundation
We know our allegiance will cure childhood cancers. We just don't know how quickly.
The most powerful thing we can do is make it possible for parents, researchers, and doctors to work together without the rigid and limiting structures of the healthcare system.
Your support gives our front line doctors, researchers, and pediatric care specialists the resources they need to give more children access to the right options, at the right time, in the right place - and as fast as humanly possible.